or Try an Advanced Search...

    Technical Analysis for IPHA - Innate Pharma S.A.

    Grade Last Price % Change Price Change
    F 1.63 -4.12% -0.07
    IPHA closed down 4.12 percent on Friday, November 22, 2024, on 79 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical IPHA trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Calm After Storm Range Contraction -4.12%
    Wide Bands Range Expansion -4.12%
    Calm After Storm Range Contraction -3.29%
    Wide Bands Range Expansion -3.29%
    Gapped Up Strength -3.29%
    Calm After Storm Range Contraction 9.40%
    Lower Bollinger Band Walk Weakness 9.40%
    Older End-of-Day Signals for IPHA ...

       Recent Intraday Alerts

    Alert Time
    Gap Down Partially Closed about 15 hours ago
    Gap Down Closed about 15 hours ago
    10 DMA Resistance about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Fell Below 10 DMA about 15 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    IPHA Chart by TradingView
    Basic chart:

    Profile

    Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity

    Is IPHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Innate Pharma Releases Its 2025 Financial Calendar
    Nov 19 Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
    Nov 8 Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
    Nov 7 Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
    Oct 14 Innate Pharma appoints Jonathan Dickinson as new CEO and Chairman of executive board
    Oct 14 Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday
    Oct 14 Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
    Sep 30 Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
    Sep 23 Innate gets FDA clearance for Phase 1 study for IPH4502 ADC candidate
    Sep 23 FDA grants IND clearance for Innate Pharma’s solid tumour trial
    See more IPHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.15
    52 Week Low 1.29
    Average Volume 10,179
    200-Day Moving Average 2.30
    50-Day Moving Average 1.96
    20-Day Moving Average 1.75
    10-Day Moving Average 1.66
    Average True Range 0.18
    RSI (14) 42.86
    ADX 30.54
    +DI 14.08
    -DI 30.75
    Chandelier Exit (Long, 3 ATRs) 1.54
    Chandelier Exit (Short, 3 ATRs) 1.82
    Upper Bollinger Bands 2.05
    Lower Bollinger Band 1.45
    Percent B (%b) 0.29
    BandWidth 34.30
    MACD Line -0.10
    MACD Signal Line -0.10
    MACD Histogram -0.0033
    Fundamentals Value
    Market Cap 131.77 Million
    Num Shares 80.8 Million
    EPS -0.85
    Price-to-Earnings (P/E) Ratio -1.92
    Price-to-Sales 3.87
    Price-to-Book 3.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.87
    Resistance 3 (R3) 1.87 1.78 1.83
    Resistance 2 (R2) 1.78 1.72 1.79 1.82
    Resistance 1 (R1) 1.71 1.68 1.75 1.71 1.80
    Pivot Point 1.62 1.62 1.64 1.63 1.62
    Support 1 (S1) 1.55 1.56 1.59 1.55 1.46
    Support 2 (S2) 1.46 1.52 1.47 1.44
    Support 3 (S3) 1.39 1.46 1.43
    Support 4 (S4) 1.39